Table 1.
GPC3-targeted cancer immunotherapy trials.
| Therapy name (Drug type) | Phase | Trial number | Eligibility | Status | Sponsor | Country |
|---|---|---|---|---|---|---|
| GPC3 Peptide Vaccine | I | UMIN 000001395 | Adult HCC | Complete | National Cancer Center Hospital East | Japan |
| II | UMIN 000002614 | Adult HCC | Complete | National Cancer Center Hospital East | Japan | |
| II | UMIN 000003696 | Adult OCCC | Complete | National Cancer Center Hospital East | Japan | |
| I | UMIN 000006357 | Pediatric GPC3+ Tumors | Complete | National Cancer Center Hospital East | Japan | |
| Codrituzumab (Monoclonal Antibody) | I | NCT 00746317 | Adult HCC | Complete | Chugai Pharmaceutical | USA |
| I | JapicCTI 101255 | Adult HCC | Complete | Chugai Pharmaceutical | Japan | |
| I* | NCT 00976170 | Adult HCC | Complete | Chugai Pharmaceutical | USA | |
| II | NCT 01507168 | Adult HCC | Complete | Hoffman-La Roche | USA | |
| I** | JapicCTI 163325 | Adult HCC | Open | Chugai Pharmaceutical | Japan | |
| ERY974 (Bispecific Antibody) | I | NCT 02748837 | Adult HCC | Open | Chugai Pharmaceutical | Multi-National |
| GAP T cells (CAR T Cell) | I | NCT 02932956 | Pediatric GPC3+ Liver Tumors | Open | Baylor College of Medicine | USA |
| GLYCAR T cells (CAR T Cell) | I | NCT 02905188 | Adult HCC | Open | Baylor College of Medicine | USA |
*
Combination with Sorafenib.
**
Combination with Atezolizumab.
Bold text refers to pediatric studies.